EUCTR2007-007648-85-AT进行中（未招募）1 期
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects with Systemic Lupus Erythematosus (SLE) who Completed the Phase 3 Protocol HGS1006-C1056 or HGS1006-C1057 - NA
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,620
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Have completed the HGS1006-C1056 or HGS1006-C1057 Protocol through the week 72 or week 48 visits, respectively.
- •2.Be able to receive the 1st dose of belimumab for HGS1006-C1074 four weeks (minimum of 2 weeks, maximum of 8 weeks) after the last dose in HGS1006-C1056 or HGS1006 C1057.
- •3.A female subject is eligible to enter the study if she is:
- •not pregnant or nursing;
- •of non-childbearing potential (ie, women who had a hysterectomy, are postmenopausal which is defined as 1 year without menses, have both ovaries surgically removed or have current documented tubal ligation); or
- •of childbearing potential (ie, women with functional ovaries and no documented impairment of oviductal or uterine function that would cause sterility). This category includes women with oligomenorrhoea [even severe], women who are perimenopausal or have just begun to menstruate. These women must have a negative urine pregnancy test at Day 0, and agree to 1 of the following:
- •-complete abstinence from intercourse from the administration of the 1st dose of study agent until 16 weeks after the last dose of study agent; or
- •-consistent and correct use of 1 of the following acceptable methods of birth control for 1 month prior to the start of the study agent and 16 weeks after the last dose of study agent:
- •implants of levonorgestrel;
- •injectable progesterone;
- •any intrauterine device (IUD) with a documented failure rate of less than 1% per year;
- •oral contraceptives (either combined or progesterone only);
- •double barrier method: ie, condom, cervical cap or diaphragm with spermicidal agent;
- •transdermal contraceptive patch;
- •male partner who is sterile prior to the female subject’s entry into the study and is the sole sexual partner for the female subject.
- •4.Have the ability to understand the requirements of the study provide written informed consent (including consent for the use and disclosure of research-related health information) and comply with the study procedures (including required study visits).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 724
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 9
排除标准
- •1.Have developed clinical evidence of significant, unstable or uncontrolled, acute or chronic diseases not due to SLE (ie, cardiovascular, pulmonary, hematologic, gastrointestinal, hepatic, renal, neurological, malignancy or infectious diseases), or experienced an adverse event (AE) in the Phase 3 study that could, in the opinion of the principal investigator, put the subject at undue risk.
- •2.Have developed any other medical diseases (eg, cardiopulmonary), laboratory abnormalities, or conditions (eg, poor venous access) that, in the opinion of the principal investigator, makes the subject unsuitable for the study.
研究者
相似试验
进行中（未招募）
1 期
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects with Systemic Lupus Erythematosus (SLE) who Completed the Phase 3 Protocol HGS1006-C1056 or HGS1006-C1057 - NDSystemic lupus erythematosus (SLE)MedDRA version: 9.1Level: LLTClassification code 10042945Term: Systemic lupus erythematosusEUCTR2007-007648-85-ITHUMAN GENOME SCIENCES INC735
进行中（未招募）
1 期
A Continuation Trial for Subjects With Lupus That Completed Protocol HGS1006-C1056 or HGS1006-C1057Systemic lupus erythematosus (SLE)MedDRA version: 14.1Level: PTClassification code 10042945Term: Systemic lupus erythematosusSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2007-007648-85-SEHuman Genome Sciences, Inc.1,620
进行中（未招募）
1 期
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects with Systemic Lupus Erythematosus (SLE) who Completed the Phase 3 Protocol HGS1006-C1056 or HGS1006-C1057Systemic lupus erythematosus (SLE)MedDRA version: 9.1 Level: LLT Classification code 10042945 Term: Systemic lupus erythematosusEUCTR2007-007648-85-FRHuman Genome Sciences, Inc.735
进行中（未招募）
1 期
A Continuation Trial for Subjects With Lupus That Completed Protocol HGS1006-C1056 or HGS1006-C1057Systemic lupus erythematosus (SLE)MedDRA version: 16.1Level: PTClassification code 10042945Term: Systemic lupus erythematosusSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2007-007648-85-CZHuman Genome Sciences, Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC)1,620
进行中（未招募）
1 期
A Continuation Trial for Subjects With Lupus That Completed Protocol HGS1006-C1056 or HGS1006-C1057Systemic lupus erythematosus (SLE)MedDRA version: 14.0 Level: PT Classification code 10042945 Term: Systemic lupus erythematosus System Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2007-007648-85-GBHuman Genome Sciences, Inc.735